PROSIEBENSAT1 MED. (OTCMKTS:PBSFF)‘s stock had its “sell” rating reiterated by stock analysts at DZ Bank AG in a research report issued on Wednesday.

Separately, Barclays PLC raised shares of PROSIEBENSAT1 MED. from an “equal weight” rating to an “overweight” rating in a research report on Wednesday, January 25th.

PROSIEBENSAT1 MED. (OTCMKTS:PBSFF) opened at 42.182 on Wednesday. PROSIEBENSAT1 MED. has a 12-month low of $33.70 and a 12-month high of $51.22. The stock has a market cap of $9.65 billion and a PE ratio of 21.732. The firm’s 50-day moving average price is $42.63 and its 200 day moving average price is $40.37.

TRADEMARK VIOLATION NOTICE: This piece was first reported by Watch List News and is the property of of Watch List News. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece can be read at http://www.watchlistnews.com/dz-bank-ag-reiterates-sell-rating-for-prosiebensat1-med-pbsff/1206360.html.

Receive News & Ratings for PROSIEBENSAT1 MED. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PROSIEBENSAT1 MED. and related companies with Analyst Ratings Network's FREE daily email newsletter.